• Devyser Diagnostics Q2 net sales fell 10.7% to SEK 60.2 million as EBIT dropped to SEK 0.5 million.
• Gross margin narrowed 8.2 percentage points to 76% as gross profit slid to SEK 45.8 million.
• Net profit edged up to SEK 1.6 million as EPS rose to SEK 0.10; operating cash flow increased to SEK 12.3 million.
• CEO Jan Wahlström said Q2 was weaker than expected due to a temporary inventory adjustment at its largest distributor, while underlying demand remains strong.
• Completed the CyberGene acquisition, won an SEK 8.9 million Italy contract, and launched One Lambda Devyser Chimerism Plus with Thermo Fisher.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Devyser Diagnostics AB published the original content used to generate this news brief on July 20, 2026, and is solely responsible for the information contained therein.